Interleukin-12: Clinical Trials

12 trials of Interleukin-12, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 terminated, 1 active not recruiting, 1 unknown. 12 Phase 2, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 7, Terminated 3, Active not recruiting 1, Unknown 1
Phase 17Terminated 3, Completed 2, Active not recruiting 1, Unknown 1

Follow Interleukin-12: new trials by email Literature Review of Interleukin-12 trials Research Report on Interleukin-12

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12, Temozolomide - Glioblastoma, Glioma
Phase 1 / Phase 2UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine102020-12-012020-06-09
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Cetuximab, Edodekin alfa, Laboratory Biomarker Analysis - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)232011-10-262026-11-18
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12 - Breast Cancer
Phase 1 / Phase 2TerminatedBeth Israel Deaconess Medical Center82009-12-012017-11-14
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
aldesleukin, recombinant interleukin-12, laboratory biomarker analysis - Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)462002-09-012013-01-16
Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
PSA prostate cancer vaccine, recombinant interleukin-12 - Prostate Cancer
Phase 2CompletedUniversity of Chicago132001-11-012014-03-07
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
rituximab, recombinant interleukin-12, laboratory biomarker analysis - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)992001-10-012013-08-26
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
recombinant interleukin-12, recombinant interferon alfa, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma
Phase 2CompletedNational Cancer Institute (NCI)602001-10-012013-06-05
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
recombinant interleukin-12 - Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Phase 2CompletedNational Cancer Institute (NCI)302001-07-012013-01-23
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
IL-12 - Head and Neck Cancer
Phase 1 / Phase 2CompletedDana-Farber Cancer Institute71999-07-012017-04-20
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
recombinant interleukin-12, laboratory biomarker analysis - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)1051998-02-012015-04-15
Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients
IL-12 - HIV Infections, Cryptosporidiosis
Phase 1 / Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)21997-09-012016-12-14
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
interleukin-12 - Epidemic Kaposi's Sarcoma, Recurrent Kaposi's Sarcoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)1997-01-012024-03-04

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, Follicular (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Lymphoma, T-Cell, Cutaneous (2)  ·  Mycosis Fungoides (2)  ·  Neoplasms (2)  ·  Sezary Syndrome (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  AIDS-related Kaposi sarcoma (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Cryptosporidiosis (1)  ·  Glioblastoma (1)  ·  Glioma (1)

Sponsors

National Cancer Institute (NCI) (7)  ·  Beth Israel Deaconess Medical Center (1)  ·  Dana-Farber Cancer Institute (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  University of Chicago (1)

Countries

United States (10)  ·  China (1)

Top investigators

A. Dimitrios Colevas, MD (1)  ·  Alain Rook (1)  ·  Anas Younes (1)  ·  Arthur White (1)  ·  David Avigan, MD (1)  ·  Hong Shen, MD (1)  ·  Renato Lenzi (1)  ·  Robert Yarchoan (1)  ·  Stephen Ansell (1)  ·  Thomas F. Gajewski, MD, PhD (1)  ·  William Carson (1)  ·  William E Carson (1)

NIH funding

N01CM17003 (2), P30CA006516 (2), N01CM00070 (1), P30CA016058 (1), R01AI041735 (1), R01CA089442 (1), U01CA062490 (1), U01CA076576 (1), U10CA025224 (1), U10CA031946 (1), UM1CA186712 (1)